Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Alnylam Pharmaceuticals (NQ: ALNY)
81.89 USD  -0.27 (-0.33%)
Official Closing Price  /  Updated: 5:38 PM EDT, Aug 23, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 796,200
Open 81.72
Bid (Size) 62.26 (1)
Ask (Size) 85.50 (1)
Prev. Close 82.16
Today's Range 81.30 - 83.98
52wk Range 60.27 - 122.86
Shares Outstanding 100,522,411
Dividend Yield N/A
Performance
YTD
+12.55%
+12.55%
1 Month
+7.24%
+7.24%
3 Month
+20.20%
+20.20%
6 Month
+0.33%
+0.33%
1 Year
-27.27%
-27.27%
Top News
More News
Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2019 and reviewed recent business... Read More
from Business Wire News Releases
Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
from PR Newswire
More News
Read More
Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
from Business Wire News Releases
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
from Business Wire News Releases
Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
from Business Wire News Releases
Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria
from Business Wire News Releases
Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results
from Business Wire News Releases
Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster
category REGN , Market News , B Riley FDR , and 16 more.
from Benzinga
Analysts Predict 13% Upside For The Holdings of RXL
category ETFs
from ETF Channel
Stocks Flashing Renewed Technical Strength: Alnylam Pharmaceuticals
from Investor's Business Daily
Stocks To Watch: Alnylam Pharmaceuticals Sees RS Rating Rise To 82
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.